Welcome to our dedicated page for Lantheus Holding SEC filings (Ticker: LNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lantheus Holdings, Inc. (NASDAQ: LNTH) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including Forms 10-K, 10-Q and 8-K. These documents offer detailed information about Lantheus’ radiopharmaceutical-focused business, financial performance, risk factors, leadership changes and material transactions.
In its Form 8-K filings, Lantheus has reported key corporate events such as quarterly and year-to-date financial results, authorization of a stock repurchase program, acquisitions of Evergreen Theragnostics and Life Molecular Imaging, and the divestiture of its SPECT business. Filings also document leadership transitions, including the planned retirement of the Chief Executive Officer, the appointment of an Executive Chairperson and interim CEO, and changes in other senior roles. These disclosures help investors understand governance and compensation arrangements, including consulting and retirement agreements.
Annual reports on Form 10-K and quarterly reports on Form 10-Q (accessible via the SEC’s EDGAR system and summarized on this page) typically contain segment information, discussion of products such as PYLARIFY, DEFINITY and Neuraceq, and descriptions of the company’s precision diagnostics, radiopharmaceutical oncology and strategic partnership activities. They also include extensive risk factor sections that discuss competitive dynamics, manufacturing and supply risks, regulatory considerations for PET imaging agents, and integration risks associated with acquisitions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as changes in outlook, major transactions, or updates on radiopharmaceutical pipeline assets like LNTH-2501 and MK-6240. Users can quickly see high-level insights from lengthy 10-K and 10-Q reports, as well as interpret 8-K items related to leadership changes or capital allocation. The filings page also surfaces insider and executive-related information reported in Forms 3, 4 and 5, allowing investors to monitor equity awards, vesting terms and other compensation-related details disclosed for Lantheus executives and directors.
Lantheus Holdings (LNTH) Form 8-K highlights: On 21-Jul-25 the company’s UK subsidiary closed the previously announced acquisition of Life Molecular Imaging Ltd. for an upfront cash payment of $350 million, securing 100 % of the target’s share capital in line with the January 2025 Sale & Purchase Agreement.
Item 7.01 discloses that a 22-Jul-25 press release (Exhibit 99.1) announced the closing and the appointment of Dr. Ludger Dinkelborg as Head of Research & Development, effective 1-Aug-25. He will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management and AI/Biomarkers Solutions, reporting to the CEO.
No financial statements or pro-forma figures accompany the filing; the report focuses solely on completion of the asset acquisition and the senior leadership change.